688739 Stock Overview
Liaoning Chengda Biotechnology Co.,Ltd. a biotechnology company, engages in the research and development, production, and sales of vaccines for human use in China.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Liaoning Chengda Biotechnology Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥27.87 |
| 52 Week High | CN¥35.71 |
| 52 Week Low | CN¥24.61 |
| Beta | 0.63 |
| 1 Month Change | 0.32% |
| 3 Month Change | -5.53% |
| 1 Year Change | -16.91% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -65.16% |
Recent News & Updates
Shareholder Returns
| 688739 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 0.9% | -1.6% | -0.4% |
| 1Y | -16.9% | -24.8% | -14.4% |
Return vs Industry: 688739 exceeded the CN Biotechs industry which returned -24.8% over the past year.
Return vs Market: 688739 underperformed the CN Market which returned -14.4% over the past year.
Price Volatility
| 688739 volatility | |
|---|---|
| 688739 Average Weekly Movement | 4.1% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 688739 has not had significant price volatility in the past 3 months.
Volatility Over Time: 688739's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 1,684 | Yu Mao | www.cdbio.cn |
Liaoning Chengda Biotechnology Co.,Ltd. a biotechnology company, engages in the research and development, production, and sales of vaccines for human use in China. It offers Chengda Suda human rabies and Chengda Libao Human Type B inactivated encephalitis vaccines.
Liaoning Chengda Biotechnology Co.,Ltd. Fundamentals Summary
| 688739 fundamental statistics | |
|---|---|
| Market cap | CN¥11.61b |
| Earnings (TTM) | CN¥465.92m |
| Revenue (TTM) | CN¥1.75b |
24.9x
P/E Ratio6.6x
P/S RatioIs 688739 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688739 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.75b |
| Cost of Revenue | CN¥286.15m |
| Gross Profit | CN¥1.46b |
| Other Expenses | CN¥998.03m |
| Earnings | CN¥465.92m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | 1.12 |
| Gross Margin | 83.65% |
| Net Profit Margin | 26.62% |
| Debt/Equity Ratio | 0.05% |
How did 688739 perform over the long term?
See historical performance and comparison